TrialCurveDATA (10-year update): reconstructed Kaplan–Meier curves
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | eClinicalMedicine. 2023 Mar 20;58:101901. doi: 10.1016/j.eclinm.2023.101901 |
|---|---|
| DOI | 10.1016/j.eclinm.2023.101901 |
| Registry | NCT00301457 |
| Phase | Phase 3 |
| Conditions | Breast Cancer |
| Interventions | Anastrozole |
| Sponsor | Maastricht University Medical Center |
| Enrolment | 1914 |
| Source licence | Figure published under CC BY 4.0 |
Adapted disease-free survival — 1660 patients who were disease-free at 3 years after randomisation
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 6-year anastrozole not reached; 3-year anastrozole not reached. Survival at 2 years (follow-up starting 3 years after randomisation): 6-year anastrozole 93%; 3-year anastrozole 93%. Hazard ratio 6-year anastrozole vs 3-year anastrozole 0.88 (95% CI 0.74–1.04).
| Arm | N | Events | Median (Years (follow-up starting 3 years after randomisation)) |
|---|---|---|---|
| 6-year anastrozole | 827 | 248 | not reached |
| 3-year anastrozole | 833 | 276 | not reached |
- 6-year anastrozole vs 3-year anastrozole: reconstructed HR 0.88 (95% CI 0.74–1.04)
Landmark survival (reconstructed)
| Time | 6-year anastrozole | 3-year anastrozole |
|---|---|---|
| 1 yr | 95.5% | 96.8% |
| 2 yr | 93.3% | 92.5% |
| 3 yr | 90.7% | 89.0% |
| 5 yr | 84.7% | 81.7% |
| 7 yr | 78.9% | 74.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.86, reconstructed 0.877 pass
Adapted overall survival — 1660 patients who were disease-free at 3 years after randomisation
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 6-year anastrozole not reached; 3-year anastrozole not reached. Survival at 2 years (follow-up starting 3 years after randomisation): 6-year anastrozole 97%; 3-year anastrozole 98%. Hazard ratio 6-year anastrozole vs 3-year anastrozole 0.91 (95% CI 0.73–1.14).
| Arm | N | Events | Median (Years (follow-up starting 3 years after randomisation)) |
|---|---|---|---|
| 6-year anastrozole | 827 | 154 | not reached |
| 3-year anastrozole | 833 | 168 | not reached |
- 6-year anastrozole vs 3-year anastrozole: reconstructed HR 0.91 (95% CI 0.73–1.14)
Landmark survival (reconstructed)
| Time | 6-year anastrozole | 3-year anastrozole |
|---|---|---|
| 1 yr | 98.5% | 99.3% |
| 2 yr | 97.2% | 97.6% |
| 3 yr | 95.2% | 95.9% |
| 5 yr | 92.1% | 91.4% |
| 7 yr | 88.2% | 87.0% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.93, reconstructed 0.914 pass
Adapted breast cancer-free interval (cumulative incidence of breast cancer events) — 1660 patients who were disease-free at 3 years after randomisation
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years (follow-up starting 3 years after randomisation): 6-year anastrozole 6%; 3-year anastrozole 7%. Hazard ratio 6-year anastrozole vs 3-year anastrozole 0.97 (95% CI 0.75–1.24).
| Arm | N | Events | Median (Years (follow-up starting 3 years after randomisation)) |
|---|---|---|---|
| 6-year anastrozole | 827 | 124 | not reached |
| 3-year anastrozole | 833 | 126 | not reached |
- 6-year anastrozole vs 3-year anastrozole: reconstructed HR 0.97 (95% CI 0.75–1.24)
Cumulative incidence (reconstructed)
| Time | 6-year anastrozole | 3-year anastrozole |
|---|---|---|
| 1 yr | 3.2% | 1.9% |
| 2 yr | 4.2% | 4.3% |
| 3 yr | 5.7% | 6.5% |
| 5 yr | 9.4% | 10.8% |
| 7 yr | 12.3% | 13.7% |
| 10 yr | 16.6% | 16.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.91, reconstructed 0.966 pass
Adapted breast cancer-specific mortality — 1660 patients who were disease-free at 3 years after randomisation
From figure panel D · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years (follow-up starting 3 years after randomisation): 6-year anastrozole 3%; 3-year anastrozole 2%. Hazard ratio 6-year anastrozole vs 3-year anastrozole 0.97 (95% CI 0.68–1.38).
| Arm | N | Events | Median (Years (follow-up starting 3 years after randomisation)) |
|---|---|---|---|
| 6-year anastrozole | 827 | 60 | not reached |
| 3-year anastrozole | 833 | 62 | not reached |
- 6-year anastrozole vs 3-year anastrozole: reconstructed HR 0.97 (95% CI 0.68–1.38)
Cumulative incidence (reconstructed)
| Time | 6-year anastrozole | 3-year anastrozole |
|---|---|---|
| 1 yr | 0.6% | 0.4% |
| 2 yr | 1.3% | 1.2% |
| 3 yr | 2.9% | 1.8% |
| 5 yr | 3.4% | 4.2% |
| 7 yr | 5.8% | 5.9% |
| 10 yr | 7.8% | 8.3% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1, reconstructed 1.03 pass
Adapted disease-free survival — Patients with an oestrogen receptor- and progesterone receptor-positive tumour (disease-free at 3 years after randomisation)
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 6-year anastrozole not reached; 3-year anastrozole not reached. Survival at 2 years (follow-up starting 3 years after randomisation): 6-year anastrozole 93%; 3-year anastrozole 92%. Hazard ratio 6-year anastrozole vs 3-year anastrozole 0.78 (95% CI 0.64–0.95).
| Arm | N | Events | Median (Years (follow-up starting 3 years after randomisation)) |
|---|---|---|---|
| 6-year anastrozole | 627 | 179 | not reached |
| 3-year anastrozole | 633 | 221 | not reached |
- 6-year anastrozole vs 3-year anastrozole: reconstructed HR 0.78 (95% CI 0.64–0.95)
Landmark survival (reconstructed)
| Time | 6-year anastrozole | 3-year anastrozole |
|---|---|---|
| 1 yr | 95.9% | 96.5% |
| 2 yr | 93.5% | 91.6% |
| 3 yr | 90.9% | 88.0% |
| 5 yr | 85.6% | 80.9% |
| 7 yr | 79.7% | 73.4% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.77, reconstructed 0.781 pass
Adapted disease-free survival — Patients with an oestrogen receptor- or progesterone receptor-positive tumour (disease-free at 3 years after randomisation)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 3-year anastrozole not reached; 6-year anastrozole not reached. Survival at 2 years (follow-up starting 3 years after randomisation): 3-year anastrozole 95%; 6-year anastrozole 92%. Hazard ratio 3-year anastrozole vs 6-year anastrozole 0.79 (95% CI 0.55–1.12).
| Arm | N | Events | Median (Years (follow-up starting 3 years after randomisation)) |
|---|---|---|---|
| 3-year anastrozole | 200 | 56 | not reached |
| 6-year anastrozole | 200 | 70 | not reached |
- 3-year anastrozole vs 6-year anastrozole: reconstructed HR 0.79 (95% CI 0.55–1.12)
Landmark survival (reconstructed)
| Time | 3-year anastrozole | 6-year anastrozole |
|---|---|---|
| 1 yr | 97.0% | 94.0% |
| 2 yr | 95.0% | 92.5% |
| 3 yr | 91.9% | 89.5% |
| 5 yr | 84.3% | 81.5% |
| 7 yr | 79.1% | 76.3% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.22, reconstructed 1.27 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/data-10-year-update-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/data-10-year-update-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: eClinicalMedicine. 2023 Mar 20;58:101901. doi: 10.1016/j.eclinm.2023.101901 doi:10.1016/j.eclinm.2023.101901. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/data-10-year-update
Report a problem with these data
Related trials
- SECRAB: Disease free survival; Local recurrence; Loco-regional in-field recurrence; Overall surviv
- PANTHER: Breast cancer recurrence-free survival events (cumulative incidence)
- FURVA: Overall survival; Progression-free survival
- PERSEPHONE: Disease-free survival; Overall survival
- FAKTION: Overall survival; Progression-free survival
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials